ARROWHEAD PHARMACEUTICALS Q2 Earnings Soar $1.07 Above Estimates, Revenues Exceed Expectations.
May 5, 2023
Trending News 🌥️
Arrowhead Pharmaceuticals ($NASDAQ:ARWR) is a biotechnology company focused on discovering, developing and commercializing innovative medicines that treat the underlying causes of disease. The company’s second quarter earnings of $0.45 per share beat analyst expectations by $1.07, coming in at an impressive $190.6 million. This number is significantly higher than the expected $179.7 million in revenue. The company’s success in this quarter can be attributed to its focus on finding treatments for serious diseases such as hepatitis B and NASH. Arrowhead has had multiple trials go well in this quarter, resulting in impressive growth and success for the company.
In addition, the company’s technological advances such as its RNAi therapy have been instrumental in its success this quarter. The strong performance in the second quarter from Arrowhead Pharmaceuticals is indicative of the growth potential of the company. With promising treatments for serious illnesses, the company is well positioned to continue its impressive streak and surpass analyst expectations for future quarters.
Earnings
In its earning report of FY2023 Q2 as of March 31 2023, ARROWHEAD PHARMACEUTICALS reported total revenue of 146.27M USD and a net income of 48.68M USD. These figures mark a 3.6% decrease in total revenue and a 9.7% increase in net income compared to the same period the previous year. Notably, the company has seen a massive surge in total revenue over the past three years, with it rising from 32.81M USD to 146.27M USD. This indicates that ARROWHEAD PHARMACEUTICALS is on an upwards trajectory and is potentially set to experience more successes in the coming quarters.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Arrowhead Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 272.8 | -150.21 | -55.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Arrowhead Pharmaceuticals. More…
| Operations | Investing | Financing |
| -244.74 | -19.04 | 312.55 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Arrowhead Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 891.31 | 426.2 | 3.53 |
Key Ratios Snapshot
Some of the financial key ratios for Arrowhead Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 25.2% | – | -53.6% |
| FCF Margin | ROE | ROA |
| -129.5% | -22.2% | -10.3% |
Share Price
On Wednesday, ARROWHEAD PHARMACEUTICALS reported their Q2 earnings that far exceeded market expectations. This impressive growth in profit and revenues demonstrates ARROWHEAD PHARMACEUTICALS’ continued success as a prominent drug developer. Live Quote…
Analysis
At GoodWhale, we have conducted a detailed analysis to evaluate ARROWHEAD PHARMACEUTICALS‘s fundamentals. Our analysis has identified ARROWHEAD PHARMACEUTICALS as a medium risk investment in terms of financial and business aspects. We have detected two risk warnings in the income sheet and cashflow statement. If you’d like to learn more about these potential risks, please register with us and check out our detailed analysis. We believe being aware of the risks associated with an investment is key to making an informed decision. More…
Peers
It also has a large marketing and sales force that helps it to sell its products to customers.
– Lin BioScience Inc ($TPEX:6696)
Sangamo Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel genomic therapies. The Company’s technology platform is based on zinc finger DNA-binding proteins (ZFPs). The Company’s product candidates are designed to target and modulate the activity of specific genes associated with disease. The Company’s lead product candidates include SB-525, which is in Phase III clinical trials for the treatment of hemophilia A, and SB-913, which is in Phase I/II clinical trials for the treatment of Mucopolysaccharidosis Type I (MPS I).
– Acer Therapeutics Inc ($NASDAQ:ACER)
Acer Therapeutics Inc is a pharmaceutical company that focuses on the development and commercialization of therapies for serious rare and life-threatening diseases. The company’s lead product candidate, Etrasimod, is in clinical development for the treatment of ulcerative colitis, Crohn’s disease, and relapsing multiple sclerosis. Acer also has a portfolio of product candidates in various stages of development for the treatment of rare genetic disorders, including Duchenne muscular dystrophy, Friedreich’s ataxia, alpha-1 antitrypsin deficiency, and Gaucher disease.
– Innovation1 Biotech Inc ($OTCPK:IVBT)
Innovation1 Biotech Inc is a company that focuses on developing innovative treatments for diseases. The company has a market cap of 1.6M as of 2022 and a Return on Equity of -5.58%. The company’s market cap is the value of its outstanding shares of stock. The company’s ROE is a measure of how much profit it generates for shareholders.
Summary
Additionally, revenue for the quarter was also higher than expected. This news pushed the stock price upwards on the same day, which is a strong sign of investor confidence in the company. Going forward, investors will be watching Arrowhead Pharmaceuticals‘ performance closely to assess whether the company can sustain its current momentum.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
